The overall goal of Dr. Jones’ research is to identify, characterize, and target metabolic vulnerabilities of leukemic stem cells in order to improve outcomes for patients with leukemia. To achieve this goal her lab uses primary leukemia specimens, patient-derived xenograft models, as well as mass spectrometry-based metabolomic and lipidomic analysis. The ultimate objective of the lab is to translate laboratory findings into the clinic and understand clinical observations through laboratory studies.
- Postdoctoral Fellow, University of Colorado
- PhD, New York University Medical Center
- Scientist, Princess Margaret Cancer Centre, University Health Network
- Investigator I, OICR
- Jones CL, Stevens BM, D’Alessandro A, …, Jordan CT. Cysteine depletion targets leukemia stem cells through inhibition of electron transport complex II. Blood. 2019; 134(4):389-394.
- Jones CL, Stevens BM, D’Alessandro A,…, Jordan CT. Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells. Cancer Cell. 2019; 35(2):333-335.
- Pollyea DA*, Stevens BM*, Jones CL*, …, Jordan CT. Venetoclax with Azacitidine Disrupts Energy Metabolism and Targets Leukemia Stem Cells in Acute Myeloid Leukemia Patients. Nature Medicine. 2018; 24(12):1859-1866.
See Dr. Jones’ recent publications on PubMed.
To collaborate with Dr. Jones, please contact her directly.
Visit OICR’s Collaborative Research Resources directory for more opportunities to collaborate with OICR researchers.